Suggested remit: To appraise the clinical and cost effectiveness of imlunestrant within its marketing authorisation for treating oestrogen receptor-positive, HER2-negative advanced breast cancer after endocrine treatment.
Status In progress
Technology type Medicine
Decision Awaiting decision
Process STA Standard
ID number 6373

Email enquiries


Key events during the development of the guidance:

Date Update
11 June 2024 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-November 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early February 2025.
25 April 2024 - 24 May 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6373
25 April 2024 In progress. Scoping commencing
25 October 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
25 October 2023 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual